Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

14-640M JAK2 Protein, active, 250 µg

14-640M
250 µg  Also available in 10 μg size (cat#14-640) and in bulk (cat# 14-640-K).
Purchase on Sigma-Aldrich

Overview

Replacement Information
Description
Catalogue Number14-640M
Brand Family Upstate
Trade Name
  • Upstate
DescriptionJAK2 Protein, active, 250 µg
OverviewC-terminal His6-tagged, recombinant, human JAK2, amino acids 808-end, expressed by baculovirus in Sf21 cells
References
Product Information
Quality LevelMQ100
Applications
ApplicationActive, C-terminal His6-tagged, recombinant, human JAK2, amino acids 808-end, expressed by baculovirus in Sf21 cells, for use in Enzyme Assays.
Key Applications
  • Enzyme Assays
Biological Information
Sourcerecombinant, human JAK2, amino acids 808-end
Specific ActivityFor Specific Activity data, refer to the Certificate of Analysis for individual lots of this enzyme.
Entrez Gene Number
Entrez Gene SummaryThis gene product is a protein tyrosine kinase involved in a specific subset of cytokine receptor signaling pathways. It has been found to be constituitively associated with the prolactin receptor and is required for responses to gamma interferon. Mice that do not express an active protein for this gene exhibit embryonic lethality associated with the absence of definitive erythropoiesis.
Gene Symbol
  • JAK2
  • OTTHUMP00000043260
  • JAK-2
Protein TargetJAK2
Purification MethodNi2+/NTA-agarose
Target Sub-FamilyTK
UniProt Number
UniProt SummaryFUNCTION: SwissProt: O60674 # Tyrosine kinase of the non-receptor type, involved in interleukin-3 and probably interleukin-23 signal transduction.
SIZE: 1132 amino acids; 130674 Da
SUBUNIT: Interacts with SIRPA (By similarity). Interacts with IL23R, SKB1 and STAM2.
SUBCELLULAR LOCATION: Intracytoplasmic membrane; Peripheral membrane protein (By similarity). Note=Wholly intracellular, possibly membrane associated (By similarity).
TISSUE SPECIFICITY: Expressed in blood, bone marrow and lymph node.
DOMAIN: SwissProt: O60674 Possesses two phosphotransferase domains. The second one probably contains the catalytic domain (By similarity), while the presence of slight differences suggest a different role for domain 1.
DISEASE: SwissProt: O60674 # Chromosomal aberrations involving JAK2 are found in both chronic and acute forms of eosinophilic, lymphoblastic and myeloid leukemia. Translocation t(8;9)(p22;p24) with PCM1 links the protein kinase domain of JAK2 to the major portion of PCM1. Translocation t(9;12)(p24;p13) with ETV6. & Defects in JAK2 are a cause of susceptibility to Budd- Chiari syndrome [MIM:600880]. Budd-Chiari syndrome is a spectrum of disease states, including anatomic abnormalities and hypercoagulable disorders, resulting in hepatic venous outflow occlusion. Clinical manifestations observed in the majority of patients include hepatomegaly, right upper quadrant pain, and abdominal ascites. & Defects in JAK2 are associated with polycythemia vera (PV) [MIM:263300]. PV, the most common form of primary polycythemia, is caused by somatic mutation in a single hematopoietic stem cell leading to clonal hematopoiesis. PV is a myeloproliferative disorder characterized predominantly by erythroid hyperplasia, but also by myeloid leukocytosis, thrombocytosis, and splenomegaly. Familial cases of PV are very rare and usually manifest in elderly patients. & Defects in JAK2 gene may be a cause of essential thrombocythemia (ET) [MIM:187950]. ET is characterized by elevated platelet levels due to sustained proliferation of megakaryocytes, and frequently lead to thrombotic and haemorrhagic complications. & Defects in JAK2 are associated with familial myelofibrosis [MIM:254450]. Myelofibrosis with myeloid metaplasia is a myeloproliferative disease with annual incidence of 0.5-1.5 cases per 100,000 individuals and age at diagnosis around 60 (an increased prevalence is noted in Ashkenazi Jews). Clinical manifestations depend on the type of blood cell affected and may include anemia, pallor, splenomegaly, hypermetabolic state, petechiae, ecchymosis, bleeding, lymphadenopathy, hepatomegaly, portal hypertension. & Defects in JAK2 are a cause of acute myelogenous leukemia (AML) [MIM:601626]. AML is a malignant disease in which hematopoietic precursors are arrested in an early stage of development.
SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein kinase family. JAK subfamily. & Contains 1 FERM domain. & Contains 1 protein kinase domain. & Contains 1 SH2 domain.
Molecular Weight38.9kDa
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Quality Assuranceroutinely evaluated by phosphorylation of PDKtide (12-401)
Usage Statement
  • Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Storage and Shipping Information
Storage Conditions6 months at -70°C
Packaging Information
Material Size250 µg
Material PackageAlso available in 10 μg size (cat#14-640) and in bulk (cat# 14-640-K).
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
Catalogue Number GTIN
14-640M 04053252324215

Related Products & Applications

Alternative Packsize

Catalogue Number Description
14-640 JAK2 Protein, active, 10 µg

Product Families

Categories

Life Science Research > Proteins and Enzymes > Purified Kinases
Life Science Research > Drug Discovery and Development > Kinase & Phosphatase Screening > Purified Kinases